Passive immunization against exposure to hepatitis B virus in the military: potential and possibilities.
The value of standard γ-globulin with a low titer of antibody to hepatitis B surface antigen (anti-HB(s)) vs hepatitis B immune globulin (HBIG) in prevention of icteric hepatitis B in the military is unclear. Although recent studies have shown a decrease in icteric hepatitis after administration of both types of γ-globulin in populations where acquisition of hepatitis B virus (HBV) is most likely the result of nonparenteral transmission, the data pertaining to parenteral exposure suggest that HBIG delays the incubation period of HBV and decreases the development of passive-active immunity. Since no studies have demonstrated efficacy of standard γ-globulin or HBIG in a drug-using population where multiple HBV exposures are likely, the results observed in most trials are not comparable to hepatitis B associated with drug abuse in the military. Therefore, before a recommendation for use of routine γ-globulin or HBIG can be made for drug-related hepatitis in the military, efficacy of standard γ-globulin and/or HBIG should be demonstrated in this population.
D006509:Hepatitis B / Q000276:immunology* / Q000628:therapy / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000032:analysis; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007110:Immunity, Active; D007112:Immunity, Maternally-Acquired; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D008887:Military Medicine; D005719:gamma-Globulins / Q000008:administration & dosage
D006510:Hepatitis B Antibodies; D007136:Immunoglobulins; D005719:gamma-Globulins